Axsome Therapeutics, Inc.
No trades
Fundamentals and stats
EPS and revenue snapshot
In the last quarter, the company reported −1.26 USD per share, beating the −0.84 USD estimate by −49.22%. Revenue for the same period reached 189.40 M USD, despite the estimate of 190.91 M USD. For the next quarter, analysts expect −0.84 USD in earnings per share and 222.25 M USD in revenue.
Next report date—
Report period—
EPS estimate—
Revenue estimate—
EPS
Reported
Estimate
Metrics
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Metrics
Reported
Estimate
Surprise